Shares of Helix BioPharma Corp. (TSE:HBP – Get Free Report) passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of C$0.92 and traded as high as C$0.95. Helix BioPharma shares last traded at C$0.95, with a volume of 2,500 shares traded.
Helix BioPharma Stock Performance
The firm’s 50-day moving average is C$0.92 and its two-hundred day moving average is C$0.98. The stock has a market cap of C$50.37 million, a P/E ratio of -1.00 and a beta of -0.84.
Helix BioPharma Company Profile
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.
Read More
- Five stocks we like better than Helix BioPharma
- What is the FTSE 100 index?
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- The 3 Best Fintech Stocks to Buy Now
- 3 Must-Own Stocks to Build Wealth This Decade
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
